Trials / Unknown
UnknownNCT05132777
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Shanghai JMT-Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JMT101 | JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks). |
| DRUG | Osimertinib Mesylate Tablets | Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks). |
Timeline
- Start date
- 2021-11-20
- Primary completion
- 2023-09-30
- Completion
- 2024-09-30
- First posted
- 2021-11-24
- Last updated
- 2021-11-24
Source: ClinicalTrials.gov record NCT05132777. Inclusion in this directory is not an endorsement.